Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2022
The study is planned to evaluate the therapeutic efficacy and safety of Ingavirin®, syrup, 30 mg/5 ml, in the treatment of influenza or other acute respiratory infections in children from 6 months to 2 years compared with placebo.
Epistemonikos ID: e58cbe7cd8e32634b4f21dcfc1cde19915466c10
First added on: Oct 02, 2023